Ranbaxy signs new R&D agreement with GSK

39820 Investors following Ranbaxy Labs. Share this News with them.

0

Like this story, share it with millions of investors on M3

Ranbaxy signs new R&D agreement with GSK

Ranbaxy signs new R&D agreement with GSK

Post your opinion here

 

0

Tweet

Share on Tumblr

RELATED NEWS Ranbaxy gains approval to mkt Amoxicillin Ranbaxy launches 2 NDDS Urology products in India Ranbaxy Laboratories may run upto Rs 450-455 Ranbaxy maintained upward momentum on QoQ ALSO READ See latest News about Ranbaxy Labs See previous management interviews See what other Experts & Brokerages are saying about Ranbaxy Labs Ranbaxy Labs BSE | NSE 28/05/12 Are Mutual Funds betting on Ranbaxy Labs?

The CEEDD, created after the initial agreement between Ranbaxy and GSK, is a small, dedicated team that contributes to the GSK pipeline solely through the efforts of its external alliances. The CEEDD effectively 'virtualizes' a portion of the GSK pipeline; namely, from target to clinical proof of concept, by forming multiple risk-sharing/reward-sharing alliances.

Welcoming the expanded agreement with GSK, Malvinder Mohan Singh, CEO and MD, Ranbaxy, said, 'This is a great moment for our scientists. The agreement presents a unique opportunity to demonstrate the India centric advantages of high quality research and development to deliver value at the cutting edge. I believe the arrangement with GSK is path-breaking and acknowledges the higher level of R&D maturity prevalent today in our state-of-the art labs in India.'

Endorsing the development, Maxine Gowen, Senior Vice President, Center of Excellence for External Drug Discovery (CEEDD), GSK, said, 'This expanded agreement builds on the success of the existing collaboration and furthers our CEEDD strategy of building a strong pipeline through to clinical Proof of Concept via external R&D collaborations.'

Reflecting on the agreement, Dr Pradip Bhatnagar, Vice President, New Drug Discovery Research, Ranbaxy, said, 'This is a win-win agreement for both companies. By collaborating with Ranbaxy's talented R&D team, GSK will be able to develop more products for patients faster and Ranbaxy will benefit from GSK's vast drug discovery and development experience.'

Sourced From: Ranbaxy Laboratories Ltd